{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:41:10Z","timestamp":1761543670865,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.cgh.2020.05.024","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T05:18:13Z","timestamp":1589951893000},"page":"2015-2019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["You Can\u2019t Have One Without the Other: Innovation and Ethical Dilemmas in Gastroenterology and Hepatology"],"prefix":"10.1016","volume":"19","author":[{"given":"Thomas","family":"Couri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Aronsohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2020.05.024_bib1","first-page":"366","article-title":"Medical advance and legal lag: hemodialysis and kidney transplantation","volume":"68","author":"Sanders","year":"1968","journal-title":"UCLA Law Rev"},{"key":"10.1016\/j.cgh.2020.05.024_bib2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1440-1797.1998.tb00353.x","article-title":"Development of ethical concepts in dialysis: Seattle in the 1960s","volume":"4","author":"Blagg","year":"1998","journal-title":"Nephrology"},{"key":"10.1016\/j.cgh.2020.05.024_bib3","first-page":"890","article-title":"God panels and the history of hemodialysis in America: a cautionary tale","volume":"14","author":"Ross","year":"2012","journal-title":"Am Med Assoc J Ethics"},{"key":"10.1016\/j.cgh.2020.05.024_bib4","first-page":"102","article-title":"They decide who lives, who dies: medical miracle puts moral burden on small committee","volume":"53","author":"Alexander","year":"1962","journal-title":"Life"},{"key":"10.1016\/j.cgh.2020.05.024_bib5","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1056\/NEJMp1014193","article-title":"Special treatment: the story of Medicare\u2019s ESRD entitlement","volume":"364","author":"Rettig","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2020.05.024_bib6","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1053\/j.gastro.2018.10.024","article-title":"Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining challenges","volume":"156","author":"Baumert","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.05.024_bib7","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1007\/s10620-013-2810-y","article-title":"Clinical outcomes of hepatitis C treated with pegylated interferon and ribavirin via telemedicine consultation in Northern California","volume":"58","author":"Rossaro","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2020.05.024_bib8","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/hep.23802","article-title":"Expanding access to hepatitis C virus treatment: Extension for Community Healthcare Outcomes (ECHO) project: disruptive innovation in specialty care","volume":"52","author":"Arora","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.05.024_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13027-016-0071-z","article-title":"Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States","volume":"11","author":"Rosenthal","year":"2016","journal-title":"Infect Agent Cancer"},{"key":"10.1016\/j.cgh.2020.05.024_bib10","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/cid\/ciu012","article-title":"Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries","volume":"58","author":"Hill","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cgh.2020.05.024_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12688\/f1000research.15892.1","article-title":"Hepatitis C elimination: challenges with under-diagnosis and under-treatment [version 1; referees: 2 approved]","volume":"8","author":"Terrault","year":"2019","journal-title":"F1000Res"},{"key":"10.1016\/j.cgh.2020.05.024_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/tid.12809","article-title":"Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient","volume":"20","author":"Campos-Varela","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cgh.2020.05.024_bib13","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1002\/hep.30540","article-title":"Increasing utilization and excellent initial outcomes following liver transplant of HCV-viremic donors into HCV-negative recipients","volume":"69","author":"Cotter","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.05.024_bib14","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1111\/ajt.15162","article-title":"Liver transplantation for HCV non-viremic recipients with HCV viremic donors","volume":"19","author":"Kwong","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cgh.2020.05.024_bib15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/lt.24838","article-title":"Utilization of hepatitis C virus RNA\u2013positive donor liver for transplant to hepatitis C virus RNA\u2013negative recipient","volume":"24","author":"Saberi","year":"2018","journal-title":"Liver Transplant"},{"key":"10.1016\/j.cgh.2020.05.024_bib16","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1111\/ajt.14381","article-title":"The American Society of Transplantation Consensus Conference on the use of hepatitis C viremic donors in solid organ transplantation","volume":"17","author":"Levitsky","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cgh.2020.05.024_bib17","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1600-6143.2008.02523.x","article-title":"Formal policies and special informed consent are associated with higher provider utilization of CDC high-risk donor organs","volume":"9","author":"Kucirka","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cgh.2020.05.024_bib18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000495263","article-title":"Use of hepatitis C positive organs: patient attitudes in urban Chicago","volume":"49","author":"Couri","year":"2019","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.cgh.2020.05.024_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2019-028957","article-title":"Informed consent, shared-decision making and a reasonable patient\u2019s wishes based on a cross-sectional, national survey in the USA using a hypothetical scenario","volume":"9","author":"James","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.cgh.2020.05.024_bib20","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/bmj.309.6948.184","article-title":"Medical ethics: four principles plus attention to scope","volume":"309","author":"Gillon","year":"1994","journal-title":"Br Med J"},{"key":"10.1016\/j.cgh.2020.05.024_bib21","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM198911303212204","article-title":"Recombinant interferon alfa therapy for chronic hepatitis C","author":"Di Bisceglie","year":"1989","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2020.05.024_bib22","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMe0901869","article-title":"A\u00a0step forward in therapy for hepatitis C","volume":"360","author":"Hoofnagle","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2020.05.024_bib23","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1046\/j.1365-2036.2002.01331.x","article-title":"Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in \u201creal world\u201d patients with chronic hepatitis C","volume":"16","author":"Gaeta","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2020.05.024_bib24","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hep.25957","article-title":"Informed deferral: a moral requirement for entry into the hepatitis C virus treatment warehouse","volume":"56","author":"Aronsohn","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.05.024_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12913-019-3956-x","article-title":"Short-term budget affordability of hepatitis C treatments for state Medicaid programs","volume":"19","author":"Chou","year":"2019","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.cgh.2020.05.024_bib26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/liv.13647","article-title":"The next wave of hepatitis C virus: the epidemic of intravenous drug use","volume":"38","author":"Shiffman","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2020.05.024_bib27","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1001\/jama.2018.15782","article-title":"Alternative state-level financing for hepatitis C treatment: the \u201cNetflix model.\u201d","volume":"320","author":"Trusheim","year":"2018","journal-title":"JAMA"},{"year":"2019","series-title":"Louisiana reaches \u2018Netflix-model\u2019 deal to tackle hepatitis C","author":"Deslate","key":"10.1016\/j.cgh.2020.05.024_bib28"},{"key":"10.1016\/j.cgh.2020.05.024_bib29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.idc.2018.02.011","article-title":"Hepatitis C care in the Department of Veterans Affairs: building a foundation for success","volume":"32","author":"Belperio","year":"2018","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.cgh.2020.05.024_bib30","unstructured":"US Department of Veterans Affairs. June 27, 2020. VA Research on Hepatitis C. US Department of Veterans Affairs. Available at: https:\/\/www.research.va.gov\/topics\/hep-c.cfm."},{"key":"10.1016\/j.cgh.2020.05.024_bib31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/MOG.0000000000000356","article-title":"Current and future pharmacologic treatment of nonalcoholic steatohepatitis","volume":"33","author":"Banini","year":"2017","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.cgh.2020.05.024_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756284818787400","article-title":"Cholestatic liver diseases: new targets, new therapies","volume":"11","author":"Santiago","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.cgh.2020.05.024_bib33","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1007\/s12325-018-0795-9","article-title":"Emerging therapies for inflammatory bowel disease","volume":"35","author":"Weisshof","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.cgh.2020.05.024_bib34","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/MIB.0000000000001153","article-title":"Variations in health insurance policies regarding biologic therapy use in inflammatory bowel disease","volume":"23","author":"Yadav","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2020.05.024_bib35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.5946\/ce.2016.49.1.30","article-title":"Novel endoscopic management of obesity","volume":"49","author":"Dargent","year":"2016","journal-title":"Clin Endosc"},{"key":"10.1016\/j.cgh.2020.05.024_bib36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/hep.26590","article-title":"Expanding access to hepatitis C virus care: a call to deconstruct individualized therapy","volume":"59","author":"Aronsohn","year":"2014","journal-title":"Hepatology"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356520306832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356520306832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:35:49Z","timestamp":1761543349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356520306832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1542356520306832"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2020.05.024","relation":{},"ISSN":["1542-3565"],"issn-type":[{"type":"print","value":"1542-3565"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"You Can\u2019t Have One Without the Other: Innovation and Ethical Dilemmas in Gastroenterology and Hepatology","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2020.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the AGA Institute","name":"copyright","label":"Copyright"}]}}